All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
The virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a panel of international experts come together to discuss the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia. Professor Andrew Davies, University of Southampton, Southampton, UK, discusses how to treat a patient with primary refractory diffuse large B-cell lymphoma (DLBCL).
Welcome to the Lymphoma Hub Satellite Symposium.
Please take a moment to complete the survey and answer the following questions to help us gauge your current understanding of the treatment options available for patients with R/R DLBCL.
Davies begins by outlining a specific patient case, caveats in the current treatment options for DLBCL, and the patterns of primary refractory DLBCL. The presentation then moves on to highlight the role of transplant in the DLBCL patient population, and introduces emerging therapeutics such as CAR T-cell therapy and novel treatment combination regimens.
Satellite Symposium | Sequencing treatment options in primary refractory DLBCL
If you would like to download the slides from Andrew Davies' presentation, click below.Download here
Dr. Andrew Davies | ASH 2017 | Key messages from session on tailoring frontline therapy in DLBCL
59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA Dr. Andrew Davies Interview topic: Key messages from the educational session on...
When will we be seeing changes in the frontline treatment of DLBCL?
During the European School of Haematology (ESH)'s 2nd How to Diagnose & Treat Lymphoma conference, the Lymphoma Hub spoke to Andrew Davies, University of Southampton, Southampton,...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox